The Therapeutic Value of 3D Printing Template Assisted 125 I Seed Implantation in the Treatment of Liver Malignant Tumor

Abstract Background: Individualized 3D-printing template (3D-PT) is developed to facilitate I125 radioactive seed implantation (RSI), while most of the previous studies were focused on the efficacy and safety profiles, study on the accuracy of I125 RSI is lacking. Therefore, the aim of this study is to evaluate the accuracy of intraoperative needle puncture and post-plan dosimetry of individualized 3D-PT assisted I125 RSI for recurrent/secondary head and neck cancer.Methods: From February 2017 to January 2020, clinical data of 41 patients (mean age, 58.5 ± 16.1 years; 28 males) with recurrent (48.8%)/secondary (51.2%) head and neck cancer underwent individualized 3D-PT assisted I125 RSI under CT guidance in our institute were retrospectively reviewed.Results: A total of 430 needles [mean, 10.5 (range 3–17) per patient] were inserted. Technical success rate was 100% without major complication. The mean needle’s entrance deviation was 0.090 cm (95% Confidence Interval, 0.081–0.098). The mean intraoperative depth and angular of the needle were consistent with that of pre-plan (6.23 ± 0.24 vs. 6.21 ± 0.24 cm, p = 0.903; 83.14 ± 3.64 vs. 83.09 ± 3.66 degrees, p = 0.985, respectively). The mean deviation between the needle’s pre-planned and intraoperative depth and angular were 0.168 ± 0.024 cm and 1.56 ± 0.14 degrees, respectively. The post-plan dosimetry parameters, including D90, D100, V100, V150, V200, conformity index, external index, and homogeneity index, were all well coordinate with pre-planned dosimetry without significant deference (all p ＞ 0.05).Conclusion: Within the limitation of this study, individualized 3D-PT assisted I125 RSI may be accurate obtaining favorable post-plan dosimetry for patients with recurrent/secondary head and neck cancer, further prospective study is warranted.

Download Full-text

The Accuracy of Individualized 3D-Printing Template-Assisted I125 Radioactive Seed Implantation for Recurrent/Metastatic Head and Neck Cancer

Frontiers in Oncology ◽

10.3389/fonc.2021.664996 ◽

2021 ◽

Vol 11 ◽

Author(s):

Bin Qiu ◽

Yuliang Jiang ◽

Zhe Ji ◽

Haitao Sun ◽

Jinghong Fan ◽

...

Keyword(s):

Head And Neck Cancer ◽

3D Printing ◽

Head And Neck ◽

Neck Cancer ◽

Mean Deviation ◽

Conformity Index ◽

Seed Implantation ◽

Significant Difference ◽

Radioactive Seed ◽

The Mean

PurposeTo evaluate the accuracy of individualized 3D-printing template-assisted I125 radioactive seed implantation (3D-PT assisted I125 RSI) for recurrent/metastatic head and neck cancer.Materials and MethodsFrom February 2017 to January 2020, clinical data of 41 patients (mean age, 58.5 ± 16.1 years; 28 males) with recurrent (48.8%)/metastatic (51.2%) head and neck cancer underwent individualized 3D-PT assisted I125 RSI under CT guidance in a single institute were retrospectively reviewed. Total 430 seed needles [mean, 10.5 (range 3–17) per patient] were inserted.ResultsAll seed needles were inserted manually in a single attempt with the technical success rate of 100% without major perioperative complications. The mean needle’s entrance deviation was 0.090 cm (95% Confidence Interval, 0.081–0.098). The mean intraoperative depth and angle of the needle were consistent with that of planned (6.23 ± 0.24 vs. 6.21 ± 0.24 cm, p = 0.903; 83.14 ± 3.64 vs. 83.09 ± 3.66 degrees, p = 0.985, respectively). The mean deviation between the needle’s planned and intraoperative depth and angle was 0.168 ± 0.024 cm and 1.56 ± 0.14 degrees, respectively. The postoperative dosimetry parameters, including D90, D100, V100, V150, V200, conformity index, external index, and homogeneity index, were all well-coordinated with planned dosimetry without significant difference (p = 0.515, 0.662, 0.958, 0.865, 0.872, 0.278, 0.456, and 0.989, respectively).ConclusionsWithin the limitation of this study, individualized 3D-PT assisted I125 RSI may be accurate in obtaining favorable postoperative dosimetry for patients with recurrent/metastatic head and neck cancer.Clinical Trial Registration[website], identifier [registration number].

Download Full-text